Breadcrumb

Breadcrumbs

Estás en:

Asset Publisher

INFORME INHATA

InformeCell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer: A Health Technology Assessment

Recomendación Final: Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer: Recommendation 

Objetivo: This health technology assessment evaluates the diagnostic accuracy, clinical utility, safety, and cost-effectiveness of cell-free circulating tumour DNA [ctDNA] blood testing (referred to in this report as “liquid biopsy”) to detect the resistance mutation epidermal growth factor receptor (EGFR) T790M in people with advanced non–small cell lung cancer (NSCLC). It also evaluates the budget impact of publicly funding liquid biopsy, as well as the experiences, preferences, and values of people with lung cancer.  

Autoría: Ontario Health

Idioma: inglés

Fuente: INAHTA

Año de publicación: 2020